Investigators at a metabolic research institute are conducting a double-blind, placebo-controlled clinical trial to evaluate a novel oral GLP-1 receptor agonist for obesity management. The initial trial protocol defined the primary endpoint as the mean absolute reduction in body mass index (BMI) at 52 weeks, which was to be analyzed using a two-sample t-test. Midway through the study, an independent data monitoring committee notes that the pooled variance of the BMI measurements is substantially larger than the variance originally estimated during the power calculation. Concerned that this high variance will prevent the study from detecting a true clinical effect, the principal investigator decides to amend the protocol. The primary endpoint is changed from a continuous variable (mean BMI reduction) to a dichotomous outcome: the proportion of participants achieving at least a 15% reduction in baseline body weight, to be analyzed using a Chi-square test. Assuming the true magnitude of the drug's effect and the total sample size remain unchanged, which of the following best describes the most likely impact of this protocol amendment on the statistical properties of the study?
- AThe probability of failing to detect a true difference () decreases because dichotomization mitigates the statistical impact of extreme outlier values.
- BThe statistical power () increases because categorical statistical tests are mathematically more robust to high variance than continuous parametric tests.
- The probability of committing a Type II error () increases due to the loss of granular quantitative information inherently present in the continuous variable.Answer
- DThe threshold for statistical significance () automatically decreases to adjust for the reduced sensitivity of the newly selected statistical test.
- EBoth the Type I error () and Type II error () probabilities remain unchanged because the underlying sample size and true clinical effect are unmodified.